We are a portfolio biotech; developing a broad range of drug programs to generate value for our stakeholders; patients, inventors and investors.
We are building a diversified clinical-stage portfolio of assets focused on high-value markets. We have over 20 programs in our core areas of biological focus cell signaling, cell stress response and immunology.
We are a team of experienced drug hunters backed by specialist long-term investors.
We build upon our collaborations with five of the world’s leading research universities, selecting and progressing high-potential discovery programs.
Series B financing
New research partnerships
In-licensing of camoteskimab
Series C financing
Connect with Us
Interested in learning more about Apollo? Contact us today. We look forward to hearing from you.